Trastuzumab: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
mNo edit summary |
||
| Line 8: | Line 8: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 11:00, 30 October 2024
In medicine and chemotherapy, trastuzumab (pronounced tras too' zoo mab), Herceptin ®, is a monoclonal antibody against the ErbB-2 receptor (HER2) that lengthens remission time in metastatic breast cancer.[1]
External links
The most up-to-date information about Trastuzumab and other drugs can be found at the following sites.
- Trastuzumab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Trastuzumab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Trastuzumab - Detailed information from DrugBank.
References
- ↑ Hudis CA (2007). "Trastuzumab--mechanism of action and use in clinical practice.". N Engl J Med 357 (1): 39-51. DOI:10.1056/NEJMra043186. PMID 17611206. Research Blogging.